HUDDINGE, Sweden, Feb. 24, 2004 (PRIMEZONE) -- The Annual General Meeting of Tripep AB will be held on 25 March 2004 at 6 p.m. at the Kilsalen Room, Berns Conference Facility, Berzelii Park, Stockholm, Sweden. In addition to the customary issues, the Annual General Meeting will consider the Board of Directors' proposal for parallel listing of the company's shares on the London Stock Exchange AIM (Alternative Investment Market), proposals on authorisation for the Board to resolve on the new issue of shares and the sale of previously re-purchased shares, and the election of a Nomination Committee. The Invitation to Attend is attached to this press release and will be published in Swedish national daily newspaper Svenska Dagbladet and the Swedish Official Gazette on 26 February 2004.
The Annual Report for 2003 will be distributed to all shareholders by mail from 9 March 2004 onwards, and simultaneously uploaded to the company's Website, www.tripep.se.
Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies:
- research and development of alfaHGA, a potential
HIV-inhibiting drug,
- preclinical research focusing on the development of therapeutic
and prophylactic vaccines against HIV and hepatitis C, and
the RAS(R) technology platform,
- producing vaccines against influenza, allergies and Alzheimer's
Disease through associated company VLP Biotech Inc.
More details on Tripep's technologies are available at its Website: www.tripep.se
This information was brought to you by Waymaker http://www.waymaker.net